Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key
Executive Summary
Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.
You may also be interested in...
Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.
Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral
Moderna maintains its lightning pace, but questions about its Phase III trial design remain.
ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.